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high co-variability, when r ≥ 0.7, for regression analysis. The results of simple linear 
regression indicated that education status accounted for the greatest variance of the 
FACIT-TB total score, when the variance explained by all other variables in the model 
is controlled for (Beta = 0.325, P < 0.001), followed by financial status and smoking 
status. ConClusions: Our results confirmed that poor educational and financial 
statuses as well as being smokers are independent determinant of poor HRQL of 
PTB patients in Iraq.
PIN88
HEALTH RELATED QUALITY OF LIFE OF PEOPLE LIVING WITH HIV/AIDS 
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objeCtives: 1) To assess the overall Quality Of Life (QOL) of people living with HIV/
AIDS (PLWHA); 2) To compare the QOL in the six domains of health; and 3) To deter-
mine any association between age, gender, educational level and QOL. Methods: 
The study design is a descriptive cross sectional survey and the study population 
included all PLWHA who have enrolled into the Anti-Retroviral Therapy pharmacy of 
the University of Benin Teaching Hospital and were currently receiving their Highly 
Active Antiretroviral Therapy (HAART) for a period of at least six months. A trained 
interviewer administered a questionnaire that collects data on socio-demographics, 
clinicals and the items of World Health Organization Quality Of Life (WHOQOL) HIV-
bref from each participant. Means, standard deviations, and statistical tests for differ-
ences were performed. Results: A total of 360 respondents were surveyed. The mean 
age of the group was 38.58 years. 262 (72.8%) of respondents were females. The overall 
QOL of respondents was good with a mean score of (3.8 ±0.81). The QOL mean score 
were highest for the spirituality/religion/personal belief domain (16.03± 0.97) and 
lowest for the social relationships domain (11.38±1.01). The age of the respondents 
showed statistically significant differences (P< 0.05) in all domains of QOL except in 
the level of independence domain. Respondents in all the age groups had poor QOL 
in the social relationships domain. Females had statistically significant higher QOL 
mean scores in the physical, psychological and spirituality/ religion/ personal beliefs 
domains (P< 0.05) compared to males. The educational level of respondents showed 
statistically significant differences (P< 0.05) in physical, psychological, social relation-
ships and spirituality/ religion/ personal beliefs domains. Respondents with Tertiary 
education had higher QOL mean scores in the six domains of health. ConClusions: 
The study revealed good overall QOL among respondents. The mean QOL scores were 
highest in the spirituality/religion/personal beliefs domain and lowest in the social 
relationships.
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objeCtives: Quality of life (QoL) has become an accepted outcome measure in 
clinical research and advances have been made in assessing the impact of many 
diseases on QoL. The current study aimed to assess health related quality of life 
(HRQL) of subjects treated for active pulmonary tuberculosis (PTB) during the course 
of tuberculosis (TB) treatment. Methods: Consecutive PTB patients treated at 
Thoracic and Respiratory Disease Specialist Centre in Baghdad, Iraq were admin-
istered a validated TB-specific instrument. The Functional Assessment of Chronic 
Illness Therapy-Tuberculosis (FACIT-TB) total score and its subscales score at onset 
of treatment, after the intensive phase, and after completion of TB treatment were 
compared. Results: A total of 136 PTB patients were included in the analysis. After 
2 months, physical well-being (PWB), functional well-being (FWB), and FACIT-TB 
total scores were significantly increased (P < 0.01). However, there were no statis-
tical significant differences in social and economic well-being (SEWB), emotional 
well-being/living with TB (EWB/TB), and spiritual well-being (SpWB) subscales score. 
Furthermore, a significant improvement was observed in overall HRQL as indicated 
by FACIT-TB total score and all subscales except SEWB and SpWB at completion of TB 
treatment. ConClusions: The gradual increase in PWB, FWB and EWB/TB subscale 
scores over the course of TB treatment indicate the positive effect of medical therapy 
on patients’ QoL. However, interventions to offset social distress and dysfunction are 
important. Therefore individual’s perception toward this dimension of QoL should be 
addressed in future research.
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A mODEL OF CLOSTRIDIUm DIFFICILE INFECTION: DYNAmIC TRANSmISSION 
BETWEEN HOSPITALS, LONG-TERm CARE FACILITIES AND COmmUNITIES
Zowall H., Brewer C., Deutsch A.
Zowall Consulting Inc., Westmount, QC, Canada
objeCtives: The transmission of C difficile infection (CDI) has recently changed, 
resulting in a five-fold increase in the incidence in the general population and an 
eight-fold increase among the elderly. We developed a simulation model to examine 
the dynamic relationship between three major subpopulations of CDI transmission: 
hospitals, long-term care facilities (LTCF), and communities, to evaluate treatment 
effectiveness and costs. Methods: A stochastic agent-tracking meta-population 
network model of CDI transmission has been developed. A framework for contagion 
dynamics between the three subpopulations (hospitals, LTCF and communities) was 
employed. We identified eight health states: susceptible, gastrointestinal exposure, 
colonized, diseased, clinically resolved colonized, relapsed, cleared, and deceased. 
Key parameters include: age-specific incidence rates, disease severity, hospital LOS, 
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objeCtives: We describe the process and progress of the Foundation for the NIH 
Biomarkers Consortium Project Team, a public-private partnership of government, 
academia, non-profit, and industry. The goal is development and qualification of 
a new community-acquired bacterial pneumonia (CABP) patient reported outcome 
(PRO) instrument incorporating reliable, well-defined, and relevant endpoints for 
patients in terms of how they feel and function in clinical trials of antibacterial drugs 
for CABP. Methods: We adhered to the FDA PRO Guidance for instrument develop-
ment and the 2010 FDA qualification process for drug development tools (DDTs). This 
guidance describes the process for DDTs intended for use in multiple drug develop-
ment programs, the goal of the current effort. Once qualified, drug developers can 
use DDTs for the qualified context in Investigational New Drug (IND) and New Drug 
Application (NDA)/Biological License Application (BLA) submissions without FDA 
reconsideration of the DDTs’ suitability. Results: The initial phase of instrument 
development included a literature review, a gap analysis, and interviews with six 
clinical experts. The most commonly reported symptoms identified by the literature 
review were cough, chest pain, dyspnea, sputum production, and fatigue. These find-
ings were used to inform the development of a study protocol and interview guide 
to elicit concepts from CABP patients. Following qualitative analysis of the interview 
transcripts, the team will draft a PRO instrument based on key concepts identified 
from CABP patients and experts. The draft PRO will be evaluated by an expert panel 
and refined through cognitive debriefing interviews with patients. ConClusions: A 
consortium-based approach will be useful and efficient in developing a new draft PRO 
measure for CABP, which incorporates published literature and data from qualitative 
interviews. The team is currently using a similar approach for development of a draft 
PRO for acute bacterial skin and skin structure infections (ABSSSI).
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objeCtives: Quality of life in HIV infected patients can be determined by a number of 
factors including severity of disease, social support and coping mechanisms. Common 
symptoms of HIV can be a key determinant of quality of life. The objective of this study 
was to examine the influence of symptoms associated with HIV disease on physi-
cal and mental of HIV infected patients in Kenya. Methods: A Kiswahili translated 
SF-12 survey was administered to newly diagnosed HIV infected patients participating 
in a randomized, controlled trial in Nairobi, Kenya between April and October 2013. 
Patients were also asked if they were experiencing common symptoms of HIV (i.e. 
fatigue, loss of appetite, depression or diarrhea) on a scale including no symptoms, 
mild, moderate or severe symptoms. SF-12 survey responses were scored to derive a 
physical component score (PCS) and mental component score (MCS). Linear regres-
sion was used to determine which symptoms were significantly associated with each 
score. Results: 135 respondents were included in the analysis with 7 observations 
removed due to missing data. Severe fatigue was associated with 15 point (p< 0.01) 
reduction in PCS while severe lack of appetite was associated with an 8.6 point (p< 0.01) 
reduction in PCS compared patients not experiencing these symptoms. Those expe-
riencing severe depression had 12.2 point (p< 0.01) lower MCS and those experiencing 
severe anxiety had 8.4 point (p< 0.01) lower MCS compared to those not experiencing 
these symptoms. ConClusions: This study is the first to examine which symptoms 
are associated with lower quality of life outcomes in a cohort of HIV infected patients 
in Kenya. The drivers of lower physical and mental may be valuable to inform clinical 
management and program planning efforts in HIV treatment and care.
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objeCtives: To assess the ability of the socio-demographic characteristics to 
predict health related quality of life (HRQL) of pulmonary tuberculosis (PTB) 
patients. Methods: The study was conducted between September 1st 2012 and July 
31st 2013, among consecutive PTB patients treated at Thoracic and Respiratory Disease 
Specialist Centre in Baghdad, Iraq. Functional Assessment of Chronic Illness Therapy-
Tuberculosis (FACIT-TB); a TB-specific HRQL instrument, along with a structured ques-
tionnaire to collect data on socio-demographic characteristics were administered. 
Standard multiple regression analysis was used to assess the ability of the socio-
demographic characteristics (age, marital status, education status, household size, 
breadwinner, financial status and smoking status) to predict HRQL of PTB patients as 
measured by FACIT-TB total score Results: Three hundred and five subjects were 
recruited over a period of 11 months. Participants ranged in age from 18 to 91 years, 
64.6% of them were male and 28.2% were illiterate. Furthermore, 50.8% of the patients 
in the sample were the major breadwinners for their families. The variables in the 
model explained 22.9% of the variance in the FACIT-TB total score, F (7,286) = 12.14, P 
< 0.001. Among the seven variables, education status, being the breadwinner, financial 
status, and smoking showed a significant bivariate relationship with the FACIT-TB 
total score. Correlations between these seven variables precluded the condition of 
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for analyzing data and p-values Results: Thirty-eight patients were included and 
the common infection types are pneumonia (N= 13); UTI (N= 12); cellutitis (N= 9) and 
sepsis (N= 9). The common pathogens are Staphylococci (19%) and Pseudomona species 
(21%). Twenty-one percent of cases used UFO® as empirical or first-line therapy. 
Combination therapies with cephalosporins (26%) or penicillins (24%) were more 
frequent. In cephalosporins combinination therapy, the most combined antibiot-
ics are 3th cephalosporins (75%). In penicillins combinination therapy, the most 
combined antibiotics is oxacillin (40%). Mean treatment duration of UFO is 9.4 days. 
There were 71% cases using common dose of UFO®, 8-12 g/day, and 29% using 
low dose, 4-6 g/day. In patients with UFO®, 74% had negative outcomes (defined 
as patient died, hypernatremia events and changed to other antibiotics) and 26% 
had positive outcomes (defined as patients discharged, disease improved and no 
recurrent fever). Most patients developed hypernatremia (serum sodium level > 145 
mEq/L) after using UFO® for 4-6 days; patients with creatinine clearance above 50 
ml/min did not develop hypernatremia. ConClusions: The serum sodium level 
didn’t increase significantly until day 4-6 after starting UFO®. For patients with 
higher baseline serum sodium level and renal dysfunction, sodium level should be 
monitored closely while using UFO®. Using UFO® as adjunct for first line or empiric 
treatments is lack of evidence. Further antibiotic prescribing regulations should be 
implemented concerning prescribing UFO®.
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ANTImALARIAL DRUGS USE PATTERN IN RETAIL OUTLETS IN ENUGU URBAN 
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objeCtives: Drugs retail outlets constitute a major source of malaria treatment 
in developing countries requiring regular and accurate information for enhanc-
ing strategies for improving the use of Artemisinin-based Combination Therapy 
(ACT). The study analyzed the demand and sales pattern of antimalarial drugs in 
private retail outlets to assess the current state of compliance to policy. Methods: 
A prospective cross-sectional survey of randomly selected drugs retail outlets in 
Enugu urban, south east Nigeria, was conducted between May and August, 2013, to 
determine the types, range, prices and sales pattern of antimalarial drugs as well 
as concomitant medications, from pharmacies and patent medicine outlets. Data 
was collected and analysed for antimalarial drugs demanded for and sold by self-
medication, treatment by retail outlets and prescription from hospitals. Results: 
With a total of 1,321 dispensed antimalarial drugs, ACTs accounted for 72.7% while 
monotherapy was 27.3%. AMFm drugs contributed 32.7% (n = 314) of ACTs. 46.5% 
(614) of the drugs were dispensed from self-treatment by patients. Treatment by the 
retail outlets accounted for 35.8% (n = 473) while 17.7% of the drugs were dispensed 
from hospital prescriptions. The median cost of the ACTs, at $3.23 is about three 
times the median cost of monotherapy ($0.97). Total cost of treatment, including 
concomitant medications averaged $3.34 (±$1.90). The AL brand was the most used 
ACT, at 69.3% (n = 666). Self-medication accounted for the highest number of mono-
therapy at 82% ConClusions: The use of ACTs as predominant antimalarial drugs 
of choice has become widespread in the retail outlets, with significant contribu-
tions from AMFm drugs. This portends positive implications on the implementation 
of antimalarial drugs policy. However costs of policy recommended drugs remain 
higher than intended and the use of monotherapy particularly through self-med-
ication is significant suggesting additional measures to directly target consumers 
for improved use of antimalarial drugs.
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objeCtives: To describe current utilization of HIV drugs in Canada. Methods: 
Longitudinal pharmacy retail data were obtained from most Canadian provinces. 
Eligible patients received their first HIV drug prescription during the selection 
period, and consistently filled subsequent prescriptions at the same pharmacy. 
Selection periods included an early cohort (initiating therapy January 2008 to 
July 2009) and a late cohort (initiating therapy August 2010 to February 2012). The 
observation period was 43 months for the early cohort and 12 months for the late 
cohort. Results: 905 patients in the early cohort and 1,411 patients in the late 
cohort were analysed. Single-tablet regimens were the initial therapy for 32% of 
patients (early cohort) and 33% (late cohort). The most commonly used regimen 
was a backbone + protease inhibitor (PI): 45% of total days on therapy (DOT) for early 
cohort, 39% for late. Darunavir was increasingly chosen as the initial PI (3% patients 
for early cohort, 16% for late). Backbone plus integrase inhibitor (II) increased from 
2% DOT (early cohort) to 11% in the late cohort. The majority of II patients were 
treatment-naïve (71%) in the late cohort, despite funding limitation to treatment-
experienced patients in most jurisdictions. After 3 years of follow-up in the early 
cohort, 45% were still on their first therapy. For early-cohort patients who switched 
to a second therapy, 33% did so within 3 months. Subsequent lines of therapy phased 
in more gradually in both cohorts. Darunavir and II use increased in later lines of 
therapy for both cohorts, but particularly for the late cohort. ConClusions: This 
research documented changing patterns for HIV drug use in Canada, with increasing 
use of darunavir and II over time (irrespective of funding restrictions) and frequent 
early therapy switches suggestive of tolerability issues.
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treatment effectiveness, recurrence rates, mortality rates, and costs. Results: In 
the general population 5% -20% of adults are estimated to be asymptomatic carri-
ers of CDI but up to 80% of the elderly in LTCF are colonized. Over 50% of cases are 
associated with hospitals and LTCFs. Growing number of cases have onset in the 
community. 9% of patients over 65 experience severe episodes compared to 4% for 
those below 65. Mortality rates for elderly are much higher. Patients over 65 experi-
ence almost twice the recurrence rate (38%), compared with younger populations 
(18% -22%). The rates for a second recurrence are 38% for those 65+ versus 24% 
below 65. The probability of recurrent CDI increases with the number of recurrences 
experienced. Recurrences were associated with major increases in hospital LOS and 
in costs. ConClusions: Our age-specific model allows to project and to quantify 
the impact of a CDI outbreak in terms of clinical burden and costs. Using a scenario-
based approach, comparisons of current treatments with the novel approach of 
duodenal infusion (fecal transplant) are carried out.
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TWO-DOSE INFLUENzA VACCINATION COVERAGE AmONG UNITED STATES 
CHILDREN, 2008-2011
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bACkgRound: Children 6 months through 18 years of age are consistently identified 
as a high-risk population for influenza infections. Since 2007, the Advisory Committee 
on Immunization Practices (ACIP) emphasized children aged 6 months to < 9 years 
receive two doses of influenza vaccine in a season. Poor compliance with this two-
dose regimen has been described in recent years. However, since ACIPs two-dose 
recommendation in 2007, predictors of two-dose compliance have not been assessed 
using population-based data. objeCtives: This study analyzed data from influenza 
seasons 2008-2011 to examine two-dose compliance for children aged 19-35 months. 
This analysis tests for significant demographic and socioeconomic differences in one- 
and two-dose influenza vaccinations. Methods: Seasonal influenza vaccinations of 
children were estimated from the National Immunization Survey (NIS). The analysis 
results were nationally representative by weighting the study population according 
to survey weights and cluster variables. Primary outcome measures were at least one 
dose and two doses of influenza vaccination during September 1 through December 
31 of the season. For each season, the proportion of children with partial and full 
influenza vaccinations were calculated. Multivariate regressions modeled the effect 
of multiple NIS factors (i.e., age, race, gender) on influenza vaccination. Results: 
For all four seasons, adjusted one-dose influenza vaccination was significantly lower 
among children 24-35 months compared to children 19-23 months (ranging from 
7.8-44.5%, p< 0.05). Furthermore, one- and two-dose influenza vaccination was lowest 
among children living below the poverty level compared to children living above the 
poverty level (ranging from 9.4-53.7%, p< 0.05). ConClusions: Policies to improve 
one- and two-dose influenza vaccination rates should target children living below 
the poverty level. Efforts to improve one-dose vaccination rates among older infant 
children should continue. Further studies are needed to determine the reasons for 
initiating influenza vaccinations among children less than 24 months of age.
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objeCtives: This study aimed to evaluate if high antibiotic consumption is explained 
by inappropriate prescribing, given current practice guidelines. This is assessed 
through measuring the proportion of Upper Respiratory Tract Infection (URTI) treated 
by GPs with Co-amoxiclav, and Urinary Tract Infection (UTI) treated with fluoroqui-
nolones, comparing across population subgroups for differential treatment pat-
terns. Methods: This cohort study included records of all Clalit members visiting 
physicians from 4300 clinical practices during 2011. Rule-based algorithms were used 
to classify multiple primary care visits into discrete URTI and UTI events and link 
these with Ab prescriptions and dispensing. Infectious events and antibiotic prescrip-
tion rates were calculated. Differences in distributions across districts and population 
subgroups were then tested with Chi-square analysis; for prescribing ratios for UTI the 
ratio for prescribing fluoroquinolones vs. Nitrofurantoin (narrow-range Ab of choice) 
were calculated. Results: 6.5 million visits for infectious diagnoses were registered 
for all 4 million enrollees. Almost 75% of the Co-amixiclav dispensed was used for 
treatment of URTI, with 6% of URTI events treated with Co-amoxiclav. Over 75% of 
fluoroquinolones dispensed were used to treat UTI, with 23% of UTI events treated 
with fluoroquinolones. Variability between districts in the use of Co-amoxiclav for 
URTI ranged between 12%-23% in adults and 5%-21% in children. Twenty percent of 
physicians were co-amoxiclav “prescribers” with high rates of URTI events treated 
with co-amoxiclav (10%-38%). Treatment of UTI events with Quinolons varied con-
siderably between 19%-52%. The proportion of Quinolons\Nitrofurantoin prescribed 
ranged between 1.4 (1.3-1.5) to 6.2 (5.5-6.8) in each district. ConClusions: Rates 
of utilizing broad-spectrum antibiotics in the community are higher than expected 
and show wide variability across country districts and between physicians This sug-
gests the need for introducing this as a quality measure and implementing targeted 
interventions to reduce inappropriate antibiotic use.
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objeCtives: To evaluate efficacy, safety (concerning hypernatremia), and usage 
of UFO® in a medical center Methods: A retrospective medical record review 
was conducted for patients who is treated with UFO® in Wan-fang hospital during 
2012/5/1 to 7/8. Patients with cancers were excluded. Patients with suspected or 
diagnosed infections and more than one dose of UFO® were included. For hyper-
natremia analysis, only included patients with serum sodium level and no hyper-
natremia events prior UFO use. Microsoft excels and student t-test were utilized 
